DBVT
Price
$8.94
Change
-$0.32 (-3.46%)
Updated
Apr 24, 04:52 PM (EDT)
Capitalization
227.13M
LXRX
Price
$0.70
Change
+$0.03 (+4.48%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
255.46M
6 days until earnings call
Ad is loading...

DBVT vs LXRX

Header iconDBVT vs LXRX Comparison
Open Charts DBVT vs LXRXBanner chart's image
DBV Technologies S.A
Price$8.94
Change-$0.32 (-3.46%)
Volume$100
Capitalization227.13M
Lexicon Pharmaceuticals
Price$0.70
Change+$0.03 (+4.48%)
Volume$76.37K
Capitalization255.46M
DBVT vs LXRX Comparison Chart
Loading...
DBVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DBVT vs. LXRX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DBVT is a StrongBuy and LXRX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (DBVT: $8.90 vs. LXRX: $0.70)
Brand notoriety: DBVT and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DBVT: 25% vs. LXRX: 38%
Market capitalization -- DBVT: $227.13M vs. LXRX: $255.46M
DBVT [@Biotechnology] is valued at $227.13M. LXRX’s [@Biotechnology] market capitalization is $255.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DBVT’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • DBVT’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than DBVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DBVT’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 6 bullish TA indicator(s).

  • DBVT’s TA Score: 5 bullish, 4 bearish.
  • LXRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LXRX is a better buy in the short-term than DBVT.

Price Growth

DBVT (@Biotechnology) experienced а +11.53% price change this week, while LXRX (@Biotechnology) price change was +37.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

DBVT is expected to report earnings on Apr 11, 2025.

LXRX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($255M) has a higher market cap than DBVT($227M). DBVT YTD gains are higher at: 199.676 vs. LXRX (-4.753). DBVT has higher annual earnings (EBITDA): -96.59M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. DBVT (46.4M). DBVT has less debt than LXRX: DBVT (8.12M) vs LXRX (108M). LXRX has higher revenues than DBVT: LXRX (31.1M) vs DBVT (0).
DBVTLXRXDBVT / LXRX
Capitalization227M255M89%
EBITDA-96.59M-184.29M52%
Gain YTD199.676-4.753-4,201%
P/E RatioN/AN/A-
Revenue031.1M-
Total Cash46.4M238M19%
Total Debt8.12M108M8%
FUNDAMENTALS RATINGS
DBVT vs LXRX: Fundamental Ratings
DBVT
LXRX
OUTLOOK RATING
1..100
3833
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3544
P/E GROWTH RATING
1..100
10016
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (58) in the Biotechnology industry is in the same range as DBVT (69). This means that LXRX’s stock grew similarly to DBVT’s over the last 12 months.

LXRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DBVT (100). This means that LXRX’s stock grew similarly to DBVT’s over the last 12 months.

DBVT's SMR Rating (96) in the Biotechnology industry is in the same range as LXRX (97). This means that DBVT’s stock grew similarly to LXRX’s over the last 12 months.

DBVT's Price Growth Rating (35) in the Biotechnology industry is in the same range as LXRX (44). This means that DBVT’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's P/E Growth Rating (16) in the Biotechnology industry is significantly better than the same rating for DBVT (100). This means that LXRX’s stock grew significantly faster than DBVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DBVTLXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
DBVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTIX30.26N/A
N/A
Artisan International Investor
JNPSX19.57N/A
N/A
Janus Henderson Small Cap Value D
MGFRX7.92N/A
N/A
MassMutual Global R4
RICIX10.25N/A
N/A
T. Rowe Price Intl Disciplined Eq I
MSDQX11.93N/A
N/A
Morgan Stanley Emerging Mkt ex China A

DBVT and

Correlation & Price change

A.I.dvisor tells us that DBVT and CRDF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DBVT and CRDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DBVT
1D Price
Change %
DBVT100%
+5.83%
CRDF - DBVT
32%
Poorly correlated
-4.10%
DTIL - DBVT
29%
Poorly correlated
+6.77%
SNPX - DBVT
29%
Poorly correlated
+8.28%
GLSI - DBVT
29%
Poorly correlated
+1.77%
LXRX - DBVT
27%
Poorly correlated
+5.38%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+4.70%
PLRX - LXRX
42%
Loosely correlated
+1.95%
ABOS - LXRX
38%
Loosely correlated
+7.84%
VCYT - LXRX
37%
Loosely correlated
+2.15%
OCUL - LXRX
36%
Loosely correlated
+0.64%
RXRX - LXRX
36%
Loosely correlated
+3.05%
More